Background
- AXL, a member of the TAM (TYRO3, AXL, and MER) family of receptor tyrosine kinases, plays a pivotal role in proliferation, survival, migration, and differentiation.
- Dysregulation of AXL signaling is linked with chemotherapy and targeted therapy resistance.
- A novel inhibitor of AXL Kinase, TP-0903, recently completed a phase 1 clinical trial for solid tumors including colorectal cancer [NCT02729298].
- It remains unclear which patients may benefit from therapies targeting AXL, given its role in both tumor cell intrinsic resistance and immune microenvironmental reprogramming.
- Here, we present a clinical and molecular characterization of AXL in colorectal cancer (CRC).